Lundbeck presented data from the TALISMAN study and AMULET trial of amlenetug for multiple system atrophy (MSA) at the ...
Repair Biotechnologies has partnered with Genevant Sciences to combine its Cholesterol Degrading Platform (CDP) mRNA ...
San Diego start-up 858 Therapeutics has raised $50 million in a Series B round led by Avidity Partners, with participation from new and existing investors. The funds will advance 858’s pipeline, ...